Related Experiment Videos
Systematic variation and differences in insulin-autoantibody measurements.
T J Wilkin1, S L Schoenfeld, J L Diaz
1Department of Medicine, University of Washington, Seattle.
Diabetes
|February 1, 1989
Summary
Insulin autoantibodies (IAAs) are investigated as autoimmune insulitis markers. Studies revealed significant assay variability due to differences in assay type and insulin ligand, highlighting the need for standardization.
Area of Science:
- Immunology
- Endocrinology
- Diabetes Research
Background:
- Insulin autoantibodies (IAAs) are explored as biomarkers for autoimmune insulitis.
- Previous reports on IAA measurement show considerable variability, hindering their clinical application.
Purpose of the Study:
- To identify reasons for discrepant IAA measurement results across different laboratories.
- To initiate standardization procedures for IAA assays.
Main Methods:
- Two international studies involving 22 centers were conducted using coded serum samples.
- Assays were evaluated for binding signal variance, assay type (liquid vs. solid phase), ligand specificity (human vs. nonhuman insulin), and nonspecific binding.
Main Results:
- Significant variance in IAA binding signals was observed, even after standardization.
- Assay type and insulin ligand species were major contributors to variability.
- Nonspecific binding significantly impacted assay performance, causing unpredictable results and difficulties in distinguishing specific IAAs.
Conclusions:
- Standardization efforts should focus on using common units, a single insulin ligand species, and methods to minimize nonspecific binding.
- Differences between liquid-phase and solid-phase assays contribute to variability and require further investigation.